Elesion Pharmaceuticals, LLC (Elesion)

Oncology Corporate Profile

HQ Location

263 13th Avenue South, Suite 375
St. Petersburg, FL 33701

Company Description

Eleison's mission is to acquire, develop, and commercialize clinical stage drug candidates for "orphan" oncology indications, providing new hope for patients with rare life-threatening diseases. In addition to ILC, Eleison is developing Glufosfamide, a Phase III drug candidate for the treatment of patients with pancreatic cancer, and is in discussions to acquire other promising candidates for rare cancers. Eleison was founded in 2009 and is headquartered in St. Petersburg, FL.

Website: http://www.eleison-pharma.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
glufosfamideglucose conjugated prodrug2nd line metastatic pancreatic cancerIII
ILClipid cisplatinOsteosarcomaII

View additional information on product candidates here »

Source: http://www.eleison-pharma.com/

Recent News Headlines

There are no news items to display